» Articles » PMID: 32319642

MicroRNA‑93 Promotes Angiogenesis and Attenuates Remodeling Via Inactivation of the Hippo/Yap Pathway by Targeting Lats2 After Myocardial Infarctionω

Overview
Journal Mol Med Rep
Specialty Molecular Biology
Date 2020 Apr 23
PMID 32319642
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Inactivation of the Hippo pathway protects the myocardium from cardiac ischemic injury. MicroRNAs (miRs) have been reported to play pivotal roles in the progression of myocardial infarction (MI). The present study examined whether miR‑93 could promote angiogenesis and attenuate remodeling after MI via inactivation of the Hippo/Yes‑associated protein (Yap) pathway, by targeting large tumor suppressor kinase 2 (Lats2). It was identified that transfection of human umbilical vein endothelial cells with miR‑93 mimic significantly decreased Lats2 expression and Yap phosphorylation, increased cell viability and migration, and attenuated cell apoptosis following hypoxia/reoxygenation injury. Moreover, increased expression of miR‑93 resulted in an improvement of cardiac function, promotion of angiogenesis and attenuation of remodeling after MI. Additionally, miR‑93 overexpression significantly decreased intracellular adhesion molecule 1 and vascular cell adhesion protein 1 expression levels, as well as attenuated the infiltration of neutrophils and macrophages into the myocardium after MI. Furthermore, it was found that miR‑93 overexpression significantly suppressed Lats2 expression and decreased the levels of phosphorylated Yap in the myocardium after MI. Collectively, the present results suggested that miR‑93 may exert a protective effect against MI via inactivation of the Hippo/Yap pathway by targeting Lats2.

Citing Articles

Non-coding RNAs as regulators of the Hippo pathway in cardiac development and cardiovascular disease.

Song M, Wang H, Liu C, Jin S, Liu B, Sun W Front Pharmacol. 2024; 15:1348280.

PMID: 38698813 PMC: 11063341. DOI: 10.3389/fphar.2024.1348280.


MicroRNAs are associated with cardiac biomarkers, cardiac structure and function and incident outcomes in heart failure.

Spahillari A, Jackson L, Varrias D, Michelhaugh S, Januzzi J, Shahideh B ESC Heart Fail. 2024; 11(3):1400-1410.

PMID: 38321808 PMC: 11098646. DOI: 10.1002/ehf2.14649.


Yes-Associated Protein and Transcriptional Coactivator with PDZ-Binding Motif in Cardiovascular Diseases.

Li R, Huang W Int J Mol Sci. 2023; 24(2).

PMID: 36675179 PMC: 9861006. DOI: 10.3390/ijms24021666.


Signaling pathways and targeted therapy for myocardial infarction.

Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G Signal Transduct Target Ther. 2022; 7(1):78.

PMID: 35273164 PMC: 8913803. DOI: 10.1038/s41392-022-00925-z.


Targeting Epigenetics and Non-coding RNAs in Myocardial Infarction: From Mechanisms to Therapeutics.

Chen J, Liu Z, Ma L, Gao S, Fu H, Wang C Front Genet. 2022; 12:780649.

PMID: 34987550 PMC: 8721121. DOI: 10.3389/fgene.2021.780649.


References
1.
Heallen T, Morikawa Y, Leach J, Tao G, Willerson J, Johnson R . Hippo signaling impedes adult heart regeneration. Development. 2013; 140(23):4683-90. PMC: 3833428. DOI: 10.1242/dev.102798. View

2.
Yates L, Norbury C, Gilbert R . The long and short of microRNA. Cell. 2013; 153(3):516-9. DOI: 10.1016/j.cell.2013.04.003. View

3.
van Empel V, Bertrand A, Hofstra L, Crijns H, Doevendans P, De Windt L . Myocyte apoptosis in heart failure. Cardiovasc Res. 2005; 67(1):21-9. DOI: 10.1016/j.cardiores.2005.04.012. View

4.
Fiedler J, Thum T . MicroRNAs in myocardial infarction. Arterioscler Thromb Vasc Biol. 2013; 33(2):201-5. DOI: 10.1161/ATVBAHA.112.300137. View

5.
Kakio T, Matsumori A, Ono K, Ito H, Matsushima K, Sasayama S . Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Lab Invest. 2000; 80(7):1127-36. DOI: 10.1038/labinvest.3780119. View